Chronic peripheral neuropathy responsive to rituximab

Reviews in Neurological Diseases

Volumn 3, Issue 2, 2006, Pages 78-81

  Kelly, John J ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

IgM monoclonal gammopathy; Myelin associated glycoprotein; Peripheral neuropathy; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; PREDNISONE; RITUXIMAB;

AGED; CASE REPORT; DISEASE SEVERITY; ELECTROMYOGRAM; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PARESTHESIA; PERIPHERAL NEUROPATHY; REVIEW; SKIN TINGLING; TREATMENT OUTCOME; UNSTEADINESS; WALKING AID;

AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MYELIN-ASSOCIATED GLYCOPROTEIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 33745591640     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Latov N, Sherman WH, Nemni R, et al. Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med. 1980;303:618-621.
2. Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies. In: Dyck PJ, Thomas PK, Griffin JW, et al, eds. Peripheral Neuropathy, 3rd ed, vol 2. Philadelphia, PA: WB Saunders; 1993:1275-1287.
3. Kissel JT, Mendell JR. Neuropathies associated with monoclonal gammopathies. Neuromuscul Disord. 1996;6:3-18.
4. Kelly JJ Jr, Adelman LS, Berkman E, et al. Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol. 1988;45: 1355-1359.
5. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann. Neurol. 1991;30: 54-61.
6. Suarez GA, Kelly JJ Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgMMGUS neuropathies are different than IgGMGUS. Neurology. 1993;43:1304-1308.
7. Quarles RH. Glycoproteins from central and peripheral myelin. In: Hashim GA, ed. Myelin: Chemistry and Biology. New York, NY: Liss; 1980:55-77.
8. King RH, Thomas PK. The occurrence and significance of myelin with unusually large periodicity. Acta Neuropathol. (Berl.). 1984;63: 319-329.
9. Kelly JJ Jr. The electrodiagnostic findings in polyneuropathies associated with IgM monoclonal gammopathies. Muscle Nerve. 1990;13: 1113-1117.
10. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain. 1994;117: 941-947.
11. Katz JS, Saperstein DS, Gronseth G, et al. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000;54:615-620.
12. Kelly JJ. Neurologic disorders in benign and malignant plasma cell dyscrasias. In: Noseworthy JL, ed. Neurologic Therapeutics. Scarborough, Ontario: Taylor and Francis; 2003:1361-1372.
13. Rituxan. Physicians' Desk Reference. 2006: 1251-1254.
14. Latov N, Sherman WH, Vlahides G. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with Rituxan. Neurology. 1999;52(suppl 2):A551.
15. Goldfarb AR, Weimer LH, Brannagan TH III. Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle Nerve. 2005;31:510-515.
16. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology. 1999;52:1701-1704.
17. Kelly JJ Jr. Neuropathies associated with anti-MAG antibodies and IgM monoclonal gammopathies. In: Latov N, Wokke JHJ, Kelly JJ Jr. (eds). Immunological and Infectious Diseases of the Peripheral Nerves. Cambridge, United Kingdom: Cambridge University Press; 1997: 175-176.